Intervention not reported
Disease‐free survival · people with non‐rhabdomyosarcoma soft tissue sarcoma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Progression‐free survival · people with non‐rhabdomyosarcoma soft tissue sarcoma
The intervention showed no clear difference in progression‐free survival (high certainty).
1 finding from 1 review
Intervention not reported
Non‐hematologic toxicity grade 3 to 4 · people with non‐rhabdomyosarcoma soft tissue sarcoma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Health‐related quality of life · people with non‐rhabdomyosarcoma soft tissue sarcoma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Overall Survival · Adults with recurrent GBM
1 finding from 1 review
Intervention not reported
Chemotherapy toxicity · Adults with recurrent GBM
1 finding from 1 review
Intervention not reported
Overall survival median · Adults with recurrent HGG
The intervention showed no clear difference in overall survival median (moderate certainty).
1 finding from 1 review
Intervention not reported
PFS Median · Adults with recurrent HGG
The intervention showed no clear difference in PFS Median (moderate certainty).
1 finding from 1 review
Intervention not reported
QoL EORTC QoL questionnaire C30; at baseline, 12 weeks and 24 weeks · Adults with recurrent HGG
1 finding from 1 review
Intervention not reported
Chemotherapy toxicity During 1st 12 weeks of treatment · Adults with recurrent HGG
1 finding from 1 review
Intervention not reported
3‐year overall survival rate (37.2/40.2 mo) · women with locally advanced uterine cervix cancer
The intervention showed no clear difference in 3‐year overall survival rate (37.2/40.2 mo) (low certainty).
1 finding from 1 review
Intervention not reported
Locaregional recurrence · women with locally advanced uterine cervix cancer
The intervention showed no clear difference in locaregional recurrence (moderate certainty).
1 finding from 1 review
Intervention not reported
Distant metastasis · women with locally advanced uterine cervix cancer
The intervention showed no clear difference in distant metastasis (moderate certainty).
1 finding from 1 review
Intervention not reported
5‐year overall survival rate (3 to 6 yr) · women with locally advanced uterine cervix cancer
The intervention showed no clear difference in 5‐year overall survival rate (3 to 6 yr) (low certainty).
1 finding from 1 review
Intervention not reported
10‐year overall survival rate (5 to 15 yr) · women with locally advanced uterine cervix cancer
The intervention showed no clear difference in 10‐year overall survival rate (5 to 15 yr) (moderate certainty).
1 finding from 1 review
Intervention not reported
5‐year disease specific survival rate (5 to 15 yr) · women with locally advanced uterine cervix cancer
The intervention showed no clear difference in 5‐year disease specific survival rate (5 to 15 yr) (moderate certainty).
1 finding from 1 review
Intervention not reported
10‐year disease specific survival rate (5 to 15 yr) · women with locally advanced uterine cervix cancer
The intervention showed no clear difference in 10‐year disease specific survival rate (5 to 15 yr) (moderate certainty).
1 finding from 1 review
Intervention not reported
3‐year relapse‐free survive rate (37.2/40.2 mo) · women with locally advanced uterine cervix cancer
The intervention showed no clear difference in 3‐year relapse‐free survive rate (37.2/40.2 mo) (low certainty).
1 finding from 1 review
Intervention not reported
5‐year relapse‐free survive rate (66 mo) · women with locally advanced uterine cervix cancer
The intervention showed no clear difference in 5‐year relapse‐free survive rate (66 mo) (low certainty).
1 finding from 1 review
Intervention not reported
3‐year local control rate (37.2/40.2 mo) · women with locally advanced uterine cervix cancer
The intervention showed no clear difference in 3‐year local control rate (37.2/40.2 mo) (low certainty).
1 finding from 1 review